Overview
Biotechnology company developing immune-based cancer therapies.
Founded
2009
Deals ยท 12mo
1
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Aspen Neuroscience | Nov 2025Participated | $115 MSeries C | |
Ensoma | May 2023Participated | $50 MSeries B | |
Shoreline Biosciences | Nov 2021Participated | $140 MOther Equity | |
Shoreline Biosciences | Apr 2021Participated | $43 MOther Equity | |
Orna Therapeutics | Feb 2021Participated | $80 MSeries A | |
HiFiBiO | Aug 2019Participated | $67 MSeries C | |
Cell Design Labs | Jun 2016Participated | $34 MOther Equity | |
Aspen Neuroscience | Nov 2025Participated | $115 MSeries C | |
Ensoma | May 2023Participated | $50 MSeries B | |
Shoreline Biosciences | Nov 2021Participated | $140 MOther Equity | |
Shoreline Biosciences | Apr 2021Participated | $43 MOther Equity | |
Orna Therapeutics | Feb 2021Participated | $80 MSeries A | |
HiFiBiO | Aug 2019Participated | $67 MSeries C | |
Cell Design Labs | Jun 2016Participated | $34 MOther Equity |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 0 | 1 |
| Series B | 0 | 1 |
| Series C+ | 0 | 2 |
| Other Equity | 0 | 3 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jun '16 | 1 |
| Jul '16 | 0 |
| Aug '16 | 0 |
| Sep '16 | 0 |
| Oct '16 | 0 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 0 |
| May '17 | 0 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 0 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 0 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 1 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 1 |
| Mar '21 | 0 |
| Apr '21 | 1 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 1 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 1 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 7 |
| Space & Frontier Tech | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 0 |
| $25M-$50M | 2 |
| $50M-$100M | 3 |
| $100M-$250M | 2 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 6 |
| Europe | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Boxer Capital | 2 |
| BVF Partners | 2 |
| Commodore Capital | 2 |
| Cormorant Asset Management | 2 |
| Janus Henderson Investors | 2 |
| LYFE Capital | 2 |
| Stork Capital | 2 |
| Wedbush Healthcare Partners | 2 |
| Ally Bridge Group | 1 |
| ARCH Venture Partners | 1 |
| Astellas Venture Management | 1 |
| Axon Ventures | 1 |
| Balyasny Asset Management | 1 |
| BeiGene | 1 |
| Bioluminescence Ventures | 1 |
| Bristol Myers Squibb | 1 |
| Cormorant Capital | 1 |
| Delian Capital | 1 |
| Delos Capital | 1 |
| Eventide Asset Management | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 0 | 0% |
| Participating | 7 | 100% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 0 | 0% |
Lead dynamics requires at least one led deal in this range
Team
Vice President, Translational Medicine
President, CEO and Founder
Global Head of Technical Operations
Associate Director
Director, Global Commercial Analytics
Founder
Senior Process Engineer
Executive Director, Head of External Scientific Collaboration
Director
Director of Process Engineering